Adage Capital Partners Gp, L.L.C. 89bio, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in 89bio, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 350,000 shares of ETNB stock, worth $3.83 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
350,000
Previous 875,000
60.0%
Holding current value
$3.83 Million
Previous $6.48 Million
58.55%
% of portfolio
0.0%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding ETNB
# of Institutions
173Shares Held
125MCall Options Held
78.7KPut Options Held
979K-
Janus Henderson Group PLC London, X016.5MShares$181 Million0.07% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$155 Million1.76% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.2MShares$112 Million3.26% of portfolio
-
Rtw Investments, LP New York, NY7.48MShares$81.9 Million0.94% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$76.8 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $509M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...